Compare Cassava Sciences Inc (FLNA) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Jumia Technologies AG - ADR — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Jumia Technologies AG - ADR trades at $6.54 (market cap $848.39M). The key difference: Jumia Technologies AG - ADR is far larger — about 16× Cassava Sciences Inc's market cap, and Jumia Technologies AG - ADR is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | JMIA | |
|---|---|---|
Market Cap | $53.14M | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $14.60 |
52-Week Low | $1.09 | $4.45 |
Enterprise Value | -$33.43M | $795.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
JMIA trades at $6.52, down 4.82% today, amid a bearish technical signal. The company reported Q1 2026 revenue growth of 39% year-over-year but missed EPS estimates, with a net income margin of -30.79%. Cash flow improved in 2025, yet profitability remains elusive with a target set for 2027. Analyst consensus is strongly bullish with 71% buy ratings, highlighting progress in African e-commerce expansion and partnerships like Starlink.
Outlook: JMIA shows operational improvements but faces significant execution risks in achieving profitability. Investment opportunity lies in market expansion and cost management, while risks include persistent losses, competitive pressures, and macroeconomic volatility in Africa. The stock's valuation at P/S of 4.17 reflects growth expectations amid high uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
